Objective To observe the clinical efficacy of Shen ling bai zhu powder in teating ulcerative colitis.Methods Sixty patients who conformed to diagnostic standards were randomly assigned into the treatment group (30 cases) and the control group (30 cases).The control group received mesalazine,while the treatment group was treated with mesalazine and Shen ling bai zhu powder at the same time.Both groups received continuous treatment for 24 weeks.By comparing the single symptom score,the traditional Chinese medicine score and the recurrence rate before and after treatment the clinical effects of both groups were evaluated.Results There was a significant difference between the total effective rate of the treatment group and the control group (83.3% vs 63.3%) (P<0.05).Compared with the control group,the curative efficacy on improving symptoms as diarrhea,bloody purulent stool,abdominal distention,poor appetite and weakness in the treatment group was more prominent,but there were no statistically significant differences.The recurrence rate in the treatment group (4.2%) was lower than the control group (33.3%),which had significant difference (P<0.05).Conclusions Shen ling bai zhu powder could significantly relieve clinical symptoms of ulcerative colitis and had low recurrence rate,which was worthy to be popularized in clinical application.%目的 探讨参苓白术散治疗溃疡性结肠炎(UC)临床疗效及其对疾病预后的影响.方法 选取UC病人60例,随机数字表法分为对照组30例,予以美沙拉嗪口服治疗;治疗组30例,加用参苓白术散颗粒冲服,观察两组总体疗效、各症状改善及复发情况.结果 治疗组总有效率为83.3%,对照组总有效率为63.3%,差异有统计学意义(P<0.05);治疗组在腹泻、脓血便、腹胀、纳差、乏力的改善方面与对照组比较,差异无统计学意义;治疗组复发率为4.2%,低于对照组33.3%,差异有统计学意义(P<0.05).结论 参苓白术散能够明显改善UC病人的主要临床症状,安全性好,复发率低,有较好的临床使用价值.
展开▼
